Christopher G. Goetz, MD:
Stock Ownership in medically-related fields: none	Intellectual Property Rights: none
Consultancies: Addex Pharma SA, Asubio, Biovail Technologies, Cleveland Medical Devices, CNS Therapeutics, Curry Rockerfeller Group, Decision Resources, Dixon Group, ICON Clinical Research, Impax Pharmaceuticals, Ingenix (i3 Research), Intec Pharmaceuticals, Kenes International, Medical Education Global Solutions, Ono Pharmaceuticals, Oxford Biomedica, Santhera, United Bioscience Corporation, UCB.	Expert Testimony: none
Advisory Boards: Addex Pharma SA, Asubio, Biovail Technologies, Cleveland Medical Devices, CNS Therapeutics, Curry Rockerfeller Group, Decision Resources, Dixon Group, ICON Clinical Research, Impax Pharmaceuticals, Ingenix (i3 Research), Intec Pharmaceuticals, Kenes International, Medical Education Global Solutions, Ono Pharmaceuticals, Oxford Biomedica, Santhera, United Bioscience Corporation, UCB.	Employment: Rush University Medical Center
Partnerships	Contracts: None
Honoraria: Movement Disorder Society, American Academy of Neurology, University of Miami, University of Pennsylvania, University of Montreal. Neurological Society.	Royalties: Royalties: Oxford University Press, Elsevier Publishers, Wolters Kluwer Health, Lippincott, Wilkins and Williams.
Grants: Funding from NIH, Michael J. Fox Foundation, NIH. Dr. Goetz directs the Rush Parkinson's Disease Research Center that receives support from the Parkinson's Disease Foundation. He directs the translation program for the MDS-UPDRS and UDysRS and receives funds from the MDS for this effort.	Other: none